Viewpoint: We’re ‘nowhere close’ to being ready to edit human genomes

| July 25, 2018
This article or excerpt is included in the GLP’s daily curated selection of ideologically diverse news, opinion and analysis of biotechnology innovation.

At a recent event with evolutionary biologist Richard Dawkins, science writer Carl Zimmer posed the following question: “There is a gene variant in some Icelanders that protects them against Alzheimer’s disease. Do you think it is ethical to give this gene to others to keep Alzheimer’s at bay?”

“By all means,” Dawkins replied. “There is nothing wrong with improving lives.”

I definitely agree with Dawkins. However, I’d add: as long as the potential benefits outweigh the risk. And with our current understanding of human physiology and genetics, that is definitely not the case.

Human beings have always yearned to better themselves – to rise beyond nature’s lottery. We are so immersed in our modern enhancements that we are often oblivious to them. LASIK surgeries (or glasses, for that matter!), cochlear implants, plastic surgeries, and birth-control pills are all examples of things we do to overcome what we perceive as our natural limitations. But what gets people really wound up is the idea of genetic enhancement – improving traits by changing the genes inside of us.

enhance 6 29 18 2
Image credit: PressTV

Gene therapy for genetic disorders – at least, those that result from a single genetic mutation – has come a long way in the past three decades. In 2017, we witnessed several milestones, including the treatment of hemophilia and of Spinal Muscular Atrophy. But gene therapy is still complicated, with severe side effects and unforeseen consequences. For example, in early 2000s, successful gene therapy for Severe Combined Immunodeficiency was overshadowed by the development of cancer in two patients. I’d argue that for deleterious mutations, the risks are justified by the promise of treating a disease. But for enhancements, we are nowhere close to a clear justification. We know of many genetic changes that in theory should create “superhuman” traits in people, but they come with debilitating consequences.

Imagine changing a single gene so that you no longer feel pain. There are people with mutations that result in not feeling pain, a condition known as congenital analgesia. Not only is this not a superpower, but people with congenital analgesia cannot live normal lives. They burn their hands on stoves without realizing, or have severe organ malfunction without feeling any pain.

Or imagine having bones that are several times denser than the average human’s, bones so dense you could get hit by a car and walk away unscathed. In reality, people with mutations that result in unbreakable bones suffer from a condition known as Sclerosteosis. Their bones can be so dense that their brains crush under the force of their own skull. One cannot help but wonder about other genetic changes that may appear to add to our human powers, but are just terrible diseases in reality. The bottom line is that we do not know all the outcomes of creating a single mutation in an individual, and chances are we will not know enough anytime soon.

Want to follow the latest news and policy debates over agricultural biotechnology and biomedicine? Subscribe to our free newsletter.
Related article:  Will 2020 see the debut of promising gene therapy for hemophilia A? It's up to the FDA.

Even if a mutation appears to have beneficial effects on the individual, we do not know all the potential side effects in the near and far future. Every now and then, based on our studies on model organisms, we come across single genes with dramatic effects on a single trait. In 1999, researchers expressed a protein that binds hippocampal receptors in the brains of mice in an attempt to improve their cognitive ability. The mice showed remarkable memory and cognitive performance, which led to the researchers naming the mice Doogie, after the genius television character Doogie Howser.

massive logoAlmost 20 years later, we now know about 35 mutations in mice that improve learning and memory. We still do not know a lot about the downside to these mice, but several strains raise alarming concerns: many of the mutations that increase cognitive ability may have detrimental effects. The Doogie mice described above may be intelligent, but they have an increased sensitivity to pain. As another example, the Hras strain of mice, may excel at solving puzzles, but they have a heightened fear response. Other strains with phenomenal intelligence at complicated tasks like solving puzzles fail at simple ones like remembering where they hid their food.

The challenges are amplified when we consider that most traits are the results of tens, hundreds, or even thousands of genes, interacting in different organs. You may want to get taller, but there are about 200 genes that play a role in determining your height in your early development. Another problem is that we only move in one direction in time: we get old. Even if you could go in all your cells and change every single one of those height-altering genes for the tallest versions possible, your body is no longer in the developmental stage for those changes to manifest themselves. You can’t become super tall or super fast if you already developed with your own average genes interacting in your body.

This takes us to a whole new level of augmentation: embryo editing. Gene editing on a single-cell embryo means that the change will be passed on to the next generation(s). However, embryo editing is still in its infancy. Even the most outstanding breakthrough in embryo editing, published last year, was met with outrage and disbelief by the scientific community; a group of prominent scientists challenged the basic tenets of the paper, arguing that editing in embryos was not achieved as seamlessly as the authors had suggested.

Overall, we are nowhere close to being able to safely edit the genomes of embryos or adults. So before we start trying to turn ourselves into Usain Bolt, let’s learn more about how our genes make us who we are.

Alireza Edraki studies natural inhibitors of CRISPR-Cas9. He studies proteins from phages that can inhibit Cas9 and his research aims to use these proteins to turn Cas9 off in human cells. Follow him on Twitter @Alirezaedraki

A version of this article was originally published on Massive’s website asWe still don’t know all the consequences of gene manipulationand has been republished here with permission.

The GLP featured this article to reflect the diversity of news, opinion and analysis. The viewpoint is the author’s own. The GLP’s goal is to stimulate constructive discourse on challenging science issues.

Share via
News on human & agricultural genetics and biotechnology delivered to your inbox.
Optional. Mail on special occasions.
Send this to a friend